Background Innovations in imaging and molecular characterisation together with novel
treatment options have improved outcomes in advanced prostate cancer. However, we still …

Background With the availability of second-generation androgen receptor inhibitors
(SGARIs), the treatment landscape has changed dramatically for patients with nonmetastatic …

Prostate cancer (PCa) is the most common cancer diagnosed in men in most developed
countries and a leading cause of cancer-related morbidity and mortality. Prostate-specific …

Abstract Background In prostate cancer (PCa), questions remain on indications for prostate-
specific membrane antigen (PSMA) positron emission tomography (PET) imaging and …

The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer
(BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds …

Background This single-arm prospective study evaluated the feasibility of a novel wrist-worn
thermal device that applies cooling to the inside of the wrist for management of bothersome …

Background Currently, several therapies are available for metastatic castration-resistant
prostate cancer (mCRPC) but no specific clinical factors to personalize treatment. We first …

Tumour classifications play a pivotal role in prostate cancer (PCa) management. It can
predict the clinical outcomes of PCa as early as the disease is diagnosed and then guide …

In 2024, there will be an estimated 1,466,718 cases of prostate cancer (PC) diagnosed
globally, of which 299,010 cases are estimated to be from the US. The typical clinical …

A recent approach to radiotherapy for prostate cancer is the administration of high doses of
radiation to the prostate while minimizing the risk of side effects. Thus, image-guided …